Legal Powerhouses Steering the Mega-Deal
The heavyweight transaction has drawn in some of the world’s most elite legal firms.
Wachtell Lipton Rosen & Katz is advising Pfizer, while Paul Weiss Rifkind Wharton & Garrison LLP represents Metsera.
If Novo Nordisk’s proposal gains traction, it could mark one of the largest biotech takeovers of the decade, reshaping the competitive landscape of the pharmaceutical world and deepening the rivalry between Novo Nordisk and Pfizer—two giants already battling for dominance in the multibillion-dollar obesity drug market.
As the clock ticks on Pfizer’s four-day window, Metsera now stands at the crossroads of a $9 billion power play—a corporate chess match where every move could redefine the future of metabolic medicine.
